These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 5549719)

  • 41. Enhanced complement-mediated lysis of type III paroxysmal nocturnal hemoglobinuria erythrocytes involves increased C9 binding and polymerization.
    Hu VW; Nicholson-Weller A
    Proc Natl Acad Sci U S A; 1985 Aug; 82(16):5520-4. PubMed ID: 3860874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The complement sensitivity on PNH cells.
    Rosse WF
    Ser Haematol; 1972; 5(3):101-14. PubMed ID: 4565709
    [No Abstract]   [Full Text] [Related]  

  • 43. Hemolysis by complement and cold-reacting antibodies: time and temperature requirements.
    Rosse WF; Adams J; Logue G
    Am J Hematol; 1977; 2(3):259-70. PubMed ID: 596370
    [No Abstract]   [Full Text] [Related]  

  • 44. [Biphasic antibody with anti-Tja specificity and of IgG type].
    Saint Paul B; Chassaigne M
    Rev Fr Transfus; 1969; 12(1):Suppl:135-8. PubMed ID: 5376609
    [No Abstract]   [Full Text] [Related]  

  • 45. Mechanisms of immune lysis of the red cells in hereditary erythroblastic multinuclearity with a positive acidified serum test and paroxysmal nocturnal hemoglobinuria.
    Rosse WF; Logue GL; Adams J; Crookston JH
    J Clin Invest; 1974 Jan; 53(1):31-43. PubMed ID: 4855546
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The haemolytic action of dapsone: changes in the red-cell membrane.
    Rasbridge MR; Scott GL
    Br J Haematol; 1973 Feb; 24(2):183-93. PubMed ID: 4713625
    [No Abstract]   [Full Text] [Related]  

  • 47. Potential errors in the laboratory diagnosis of paroxysmal nocturnal hemoglobinuria.
    Harruff RC; Rohn RJ
    Am J Clin Pathol; 1983 Aug; 80(2):152-8. PubMed ID: 6881089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunobiology of complement.
    Burkholder PM; Littleton CE
    Pathobiol Annu; 1971; 1():215-39. PubMed ID: 4129958
    [No Abstract]   [Full Text] [Related]  

  • 49. Biochemistry of PNH cells: nature of the membrane defect.
    Mengel CE; Ebbert L; Stickney D; Essig L; Brubaker L
    Ser Haematol; 1972; 5(3):88-100. PubMed ID: 4641079
    [No Abstract]   [Full Text] [Related]  

  • 50. Induction of the paroxysmal nocturnal hemoglobinuria phenotype in normal human erythrocytes: effects of 2-aminoethylisothiouronium bromide on membrane proteins that regulate complement.
    Ezzell JL; Wilcox LA; Bernshaw NJ; Parker CJ
    Blood; 1991 Jun; 77(12):2764-73. PubMed ID: 1710519
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Paroxysmal nocturnal hemoglobinuria. Alternate-complement-pathway-mediated lysis induced by magnesium.
    May JE; Rosse W; Frank MM
    N Engl J Med; 1973 Oct; 289(14):705-9. PubMed ID: 4727529
    [No Abstract]   [Full Text] [Related]  

  • 52. Normal human lymphocytes treated in vitro with the sulfhydryl compound AET: relationship to the lymphocytes of paroxysmal nocturnal hemoglobinuria.
    Sirchia G; Ferrone S
    Blood; 1971 May; 37(5):563-7. PubMed ID: 5554214
    [No Abstract]   [Full Text] [Related]  

  • 53. Erythrocytes of patients with paroxysmal nocturnal haemoglobinuria acquire resistance to complement attack by purified 20-kD homologous restriction factor.
    Okada N; Harada R; Okada H
    Clin Exp Immunol; 1990 Apr; 80(1):109-13. PubMed ID: 1691059
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Red-cell abnormalities in HEMPAS (hereditary erythroblastic multinuclearity with a positive acidified-serum test).
    Crookston JH; Crookston MC; Rosse WF
    Br J Haematol; 1972 Sep; 23():Suppl:83-91. PubMed ID: 4567203
    [No Abstract]   [Full Text] [Related]  

  • 55. Comparison of the sensitivity to agglutination and haemolysis by a high-titre cold antibody of the erythrocytes of normal subjects and of patients with a variety of blood diseases including paroxysmal nocturnal haemoglobinuria.
    LEWIS SM; DACIE JV; TILLS D
    Br J Haematol; 1961 Jan; 7():64-72. PubMed ID: 13761757
    [No Abstract]   [Full Text] [Related]  

  • 56. Erythrocyte membrane interactions with menadione and the mechanism of menadione-induced hemolysis.
    Mezick JA; Settlemire CT; Brierley GP; Barefield KP; Jensen WN; Cornwell DG
    Biochim Biophys Acta; 1970 Dec; 219(2):361-71. PubMed ID: 5497195
    [No Abstract]   [Full Text] [Related]  

  • 57. Expression of cryptantigen Th on paroxysmal nocturnal hemoglobinuria erythrocytes in association with a hemolytic exacerbation.
    Nakakuma H; Hidaka M; Nagakura S; Nishimura Y; Iwamoto N; Horikawa K; Kawaguchi T; Kagimoto T; Takatsuki K
    J Clin Invest; 1995 Jul; 96(1):201-6. PubMed ID: 7542278
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Erythrocyte sensitivity to in-vitro lysis in leukaemia.
    Catovsky D; Lewis SM; Sherman D
    Br J Haematol; 1971 Nov; 21(5):541-50. PubMed ID: 5286440
    [No Abstract]   [Full Text] [Related]  

  • 59. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria.
    Holguin MH; Wilcox LA; Bernshaw NJ; Rosse WF; Parker CJ
    J Clin Invest; 1989 Nov; 84(5):1387-94. PubMed ID: 2478585
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.
    Lindorfer MA; Pawluczkowycz AW; Peek EM; Hickman K; Taylor RP; Parker CJ
    Blood; 2010 Mar; 115(11):2283-91. PubMed ID: 20068220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.